A technician conducts cell culture experiments at a TJ Biopharma research and development center in Shanghai. [Photo provided to China Daily]

A technician conducts cell culture experiments at a TJ Biopharma research and development center in Shanghai. [Photo provided to China Daily]

China approves Biogen's CD38 antibody felzartamab for multiple myeloma, its first approval anywhere, months after a $100M TJ Biopharma deal.